Showing 8,841 - 8,860 results of 20,803 for search '(( 50 ((((mean decrease) OR (we decrease))) OR (nn decrease)) ) OR ( 5 mg decrease ))', query time: 0.71s Refine Results
  1. 8841

    Table_3_Bioactive metabolites of Streptomyces misakiensis display broad-spectrum antimicrobial activity against multidrug-resistant bacteria and fungi.doc by Rewan Abdelaziz (12961639)

    Published 2023
    “…</p>Methods<p>We isolated Streptomyces species from soil samples and identified the most active strains with antimicrobial activity. …”
  2. 8842

    Table_4_Bioactive metabolites of Streptomyces misakiensis display broad-spectrum antimicrobial activity against multidrug-resistant bacteria and fungi.doc by Rewan Abdelaziz (12961639)

    Published 2023
    “…</p>Methods<p>We isolated Streptomyces species from soil samples and identified the most active strains with antimicrobial activity. …”
  3. 8843

    Image_4_Bioactive metabolites of Streptomyces misakiensis display broad-spectrum antimicrobial activity against multidrug-resistant bacteria and fungi.jpeg by Rewan Abdelaziz (12961639)

    Published 2023
    “…</p>Methods<p>We isolated Streptomyces species from soil samples and identified the most active strains with antimicrobial activity. …”
  4. 8844

    ONO-1301 enhanced SDF-1 secretion and BMC migration via SDF-1/CXCR4 signaling after MI. by Yukiko Imanishi (435069)

    Published 2013
    “…When BMCs treated with AMD were injected, the BMC accumulation decreased in the 100 mg/Kg ONO-1301-treated infarcted heart compared with the untreated-BMC-injected heart (0 mg/Kg, n = 4; 10 mg/Kg, n = 8; 100 mg/Kg, n = 5; 100 mg/Kg+AMD3100, n = 4; *<i>P</i><0.05 vs. 0 mg/Kg, †<i>P</i><0.05 vs. 10 mg/Kg, ‡<i>P</i><0.05 vs. 100 mg/Kg).…”
  5. 8845

    PA5369 Is Involved in Adhesiveness and Ability of MDR25 and MPAO1 to Disrupt Epithelial Integrity by Olga Zaborina (40802)

    Published 2008
    “…<div><p>(A) Anti-PA5369 antibodies decrease the adhesiveness of strain MDR25 to Caco-2 monolayers<i>.…”
  6. 8846

    DataSheet_1_TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.pdf by Maria Cristina Puzzolo (10649975)

    Published 2021
    “…We documented a progressive decrease of CD3+CD4+IL-4+ T cells (Th2), that was significant at M8 and at M12 (p=0.019, p=0.002), a relative increase in the CD3+CD4+IFNγ+ T cells (Th1) and a decrease of CD3+CD4+IL-17+ (Th17) cells that was maintained up to M18 (M8 vs D0 p=0.003, M12 vs D0 p=0.003, M18 vs D0 p=0.004) of ibrutinib treatment. …”
  7. 8847

    Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes by François Dion (3990335)

    Published 2017
    “…Further, glucose tolerance tests indicated an increase of 25% in glycemia in chronic kidney disease rats (p<0.0001) as compared to controls whereas insulin levels remained unchanged. We also observed modulation of glucose transporters expression in several tissues such as the liver (decrease of ≈40%, p≤0.01) and muscles (decrease of ≈29%, p≤0.05). …”
  8. 8848

    Image2_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  9. 8849

    Image1_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  10. 8850

    Table4_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  11. 8851

    Image3_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.pdf by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  12. 8852

    Table3_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  13. 8853

    Image4_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.pdf by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  14. 8854

    Table2_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  15. 8855

    Table1_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.docx by Cristina López (2841392)

    Published 2024
    “…</p>Objective<p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.</p>Methods<p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. …”
  16. 8856

    ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML by Marta E. Capala (652765)

    Published 2014
    “…Finally, ELMO1 depletion caused a marked decrease in SDF1-induced chemotaxis of leukemic cells. …”
  17. 8857

    Supplementary file 1_Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III tria... by Huaxiang Liu (322464)

    Published 2025
    “…</p>Results<p>Ivarmacitinib 4 mg (7.4%) and 8 mg (5.3%) groups had significantly lower rates of adding/escalating medication compared to the placebo group (22.3%) within W24 (both P < 0.001). …”
  18. 8858

    Image 1_Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial.tif by Huaxiang Liu (322464)

    Published 2025
    “…</p>Results<p>Ivarmacitinib 4 mg (7.4%) and 8 mg (5.3%) groups had significantly lower rates of adding/escalating medication compared to the placebo group (22.3%) within W24 (both P < 0.001). …”
  19. 8859

    Comparison of Mycoplasma gallisepticum Infection in Different Samples and Ages of Chicken Breeder Flocks by SK Demirbilek (10447241)

    Published 2021
    “…Also, 900 blood samples from the same 5 breeder flocks suffering from respiratory disease problems were tested by MG-ELISA. …”
  20. 8860

    Effect of organic cultivation of rooibos tea plants (<i>Aspalathus linearis</i>) on soil nutrient status in Nieuwoudtville, South Africa by Samson BM Chimphango (806422)

    Published 2016
    “…Compared with the uncultivated plots, no measured soil nutrients including concentrations of phosphorus (P), exchangeable potassium (K), magnesium (Mg) and calcium (Ca), and soil carbon (C) decreased in cultivated plots over the five-year period of assessment. …”